BioWorld

Nov. 25, 2008

Alpharma Rethinks King's Bid, Agrees to be Acquired for $1.6B

Two months after urging shareholders to reject a $37-per-share offer from King Pharmaceuticals Inc., Alpharma Inc. changed its mind and agreed to the merger, which values the specialty pharma firm at about $1.6 billion. (BioWorld Today) Read More

J&J Seeks to Acquire Omrix in $438M Cash Tender Offer

Host Cell Components Promising Broad-Spectrum Antiviral Targets

NewCo News: Compellis Does Obesity Drug Development by the Nose

Another Depomed Deal: $68M Delivery License with Covidien

Naproxcinod Meets Endpoints in Third Phase III Arthritis Trial

Other News To Note

Clinic Roundup

Financings Roundup

Today's news in brief

BioWorld

BioWorld briefs for Dec. 10, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 10, 2025.

Epigenetic technology could eliminate misfolded prion proteins

BioWorld Science

The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Brenig Therapeutics discovers new LRRK2 inhibitors

BioWorld Science

Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...